The Canadian Hemophilia Society – Shire Fellowship was created to engage hemophilia program professionals/graduate students from the disciplines of nursing, physiotherapy, social work and other related allied health disciplines in research focused on improving services and quality of life for people and families whose lives are affected by inherited bleeding disorders.
The fellowship was made possible thanks to generous financial support from Shire.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. Shire has best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics. Its employees work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
The CHS was proud to be in a partnership with Shire in order to offer this important fellowship program.
This program offered one or more fellowships not exceeding total funding of $20,000.
Depending upon the number and quality of applications, funding for different amounts was possible, as was the offering of more than one fellowship, within the allotted total budget stated above.
The major portion of the grant was be to cover the research time for the successful candidate(s). A small amount could be devoted to project expenses.
Fellowships were offered for a one-year period starting in April 2017.
It should be noted that allocation of this grant for future years is conditional to the CHS having received from Shire funding confirmation.
The assessment of therapeutic relationships in hemophilia care
University of Alberta – Edmonton, Alberta
One year fundingCo-PI and supervisor:
Dr. Douglas Gross
University of Alberta – Edmonton, AlbertaPeople with hemophilia have a lifelong risk for bleeding into joints and muscles. The blood causes damage over time, and they begin to experience stiffness and pain, making it difficult to do their regular activities. Physiotherapists and patients with hemophilia are partners in managing these problems. Research shows that when patients and physiotherapists have a positive relationship, patients may experience less pain, achieve higher levels of physical functioning, and greater satisfaction with care. The hemophilia community generally agrees that a good patient-provider relationship is an important aspect of treatment. However, there has been little research evaluating the quality of the patient-physiotherapist relationship, and the little information available is scattered in many different places.
This project is a scoping review. We will search for and compile the research information, to clarify whether a good way of evaluating patient-physiotherapist relationships exists. If there is not, then the next step will be to create an assessment tool. Once there is an established tool, we can begin in-depth research to understand how we can optimize patient physiotherapist relationships, and how optimization might enhance treatment outcomes. Ultimately, this will lead to improved physiotherapy care for patients with hemophilia.